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Abstract 
 
Clinical evaluation of a colchicine specific antigen-binding fragment (Fab) in order to treat colchicine 
poisoning required the development of an accurate method allowing quantification of free and Fab- 
bound colchicine in plasma and urine, and free colchicine in tissues, to measure colchicine 
redistribution after Fab administration. Three methods have been developed for this purpose, and 
validated in plasma, urine and liver: total colchicine was determined after denaturation of Fab by 
dilution in water and heating; free colchicine was separated from Fab-bound colchicine by filtration 
with 30 KDa micro-filters; tissues were homogenized in a tissue mixer. Deuterated colchicine was 
used as internal standard. Samples were extracted by liquid-liquid extraction and analyzed with a LC- 
MS/MS. LOQ were 0.5 ng/mL in plasma and urine for free and total colchicine and 5 pg/mg in tissues. 
The methods were linear in the 0.5-100 ng/mL range in plasma and urine, and 5-300 pg/mg in tissues 
with determination coefficients > 0.99. Precision and accuracy of QC samples presented a CV < 9.4%. 
The methods require only 200 µl of sample and allow a high throughput due to short analytical run (2 
min). These methods were successfully applied to a pig intoxicated with colchicine and treated with 
colchicine specific Fab fragments. 
Keywords: colchicine; toxicology; mass spectrometry; immunoglobulin Fab fragments; antidote 
 
 
 
 
1. Introduction 
 
Colchicine is a tricyclic alkaloid extracted from Colchicum autumnale, used since historic times for 
acute gout [1]. Nowadays, colchicine is indicated in gouty arthritis, Behçet disease [2] and 
Mediterranean fever [3]. Colchicine is a potent inhibitor of tubulin polymerization and microtubules 
genesis, blocking cell mitosis and neutrophil phagocytosis. 
Colchicine presents a variable oral bioavailability ranging from 18 to 79% (mean 45%) among healthy 
volunteers and elderly people [4]. After oral administration of 1 mg of colchicine, plasma peak 
concentration is observed between 0.5 and 1.5 hours [5]. Colchicine is well distributed in tissues, with 
a distribution half-life and volume respectively ranging from 0.9 to 1.4 hours and 2.3 to 8.5 L/Kg [4]. 
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Among healthy subjects, the terminal half-life varies from 23 to 41 hours [4]. Less than 40% of a 
labeled oral dose of colchicine is excreted in urine [6]. 
Colchicine therapeutic dose is 0.015 mg/Kg, it can be toxic from 0.1 mg/Kg and lethal at 0.8 mg/Kg, 
exhibiting a narrow therapeutic index [7]. Intoxications are rare, but they are associated with high 
mortality [8–16]. The course of colchicine toxicity can be divided in three phases [17,18]. The first 
occurs within the first 24h after ingestion, with gastrointestinal symptomatology (mainly diarrhea). 
The second develops from 24 h to 72 h, and is manifested by multiorgan failure: disseminated 
intravascular coagulation (DIC), renal, liver, respiratory, bone marrow and cardiac failure. The third 
stage is characterized by organ recovery associated with a leukocytosis and alopecia. Currently, there 
is no treatment available for colchicine intoxication. Colchicine has been reported to be non-dialyzable 
due to a high distribution volume, and a low body clearance [19]. Colchicine presents a high 
dissociation constant (10-6 to 10-7 M at 37°C) with tubulin, with a dissociation half-life of the complex 
tubulin-colchicine ranging from 20 to 30 hours [20]. This observation explains the long colchicine 
half-life (20-60 h) among intoxicated patients which is closely related to the complex dissociation 
[21,22]. Following these observations, an immunotoxicotherapy was developed using colchicine 
specific fragment antigen-binding (Fab). This therapy was successfully applied in a murine model 
intoxicated with colchicine lethal doses [23]. In rabbits, after a non-lethal dose of colchicine, Fab alter 
colchicine disposition with an important redistribution from tissues to blood [24]. In 1995, a clinical 
case of colchicine intoxication was successfully treated with Fab [8]. Thereafter, in 1996, spongiform 
encephalopathy and mad cow disease have spread in Europe, and colchicine specific Fab production 
from ovine origin was stopped in France. Recently, a new colchicine specific Fab has been developed, 
with a high affinity for colchicine (Ka = 1011 M-1) [25]. 
The evaluation of treatment efficacy required a specific analytical method allowing free and Fab- 
bound colchicine to be distinguished following colchicine specific Fab treatment. A previous method 
was developed by radioimmunoassay (RIA) with colchicine specific antiserum, but RIA is used less 
today due to environmental and economic issues [26]. We present here two rapid and sensitive mass 
spectrometric methods able to assess free and total (free + Fab-bound) colchicine in plasma and urine, 
and a third assay in organs. 
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2. Material and methods 
 
2.1. Chemicals and reagents 
 
The HPLC grade acetonitrile, MS grade water, isopropanol and hexane were provided by Merck 
(Darmstadt, Germany). Ammonium formate, formic acid and dichloromethane standards were 
supplied by Sigma Aldrich (Saint-Louis, USA). Colchicine was provided from LGC standards 
(Teddington, United Kingdom) and colchicine D-3 from Toronto Research Medical (Toronto, 
Canada). Potassium dihydrophosphate (KH2 PO4) was purchased from VWR (Radnor, USA). 
Colchicine-specific Fab fragments were provided by Micropharm (Newcastle Emlyn, UK). Microcon 
 
centrifugal filters 30 KDa were purchased from Millipore (Merck, Darmstadt, Germany). 
 
2.2. Standard and quality control solutions 
 
Stock solutions of colchicine and colchicine D-3 (1 mg/mL) were prepared in methanol and stored for 
one year at – 20°C. Standards solutions were wrapped in aluminium foil to prevent photodegradation 
of colchicine. Working solutions of colchicine for calibration standards (CS) were prepared at three 
concentrations (1, 0.1 and 0.01 µg/mL) by dilution in MS grade water of the stock solution. Working 
solution of colchicine for quality control (QC) was prepared from another 1 mg/mL stock solution. A 
working internal standard solution (0.1 µg/mL) was prepared by dilution of colchicine D-3 stock 
solution with MS grade water. 
2.3. LC-MS/MS 
 
Colchicine concentrations were measured using an UPLC system (Dionex Ultimate 3000, Thermo, 
USA) coupled with a tandem mass spectrometer (TSQ Quantiva, Thermo, USA). Analyte separation 
was carried out on a Hypersil GOLD Thermo column (100 x 2.1mm, 1.9 µm) maintained at 30°C. The 
device was completed with a pre-column (Thermo Hypersil GOLD 10 x 2.1mm, 5µm). Elution was in 
isocratic mode with a mobile phase composed by a mixture of 2 mM ammonium formate containing 
0.1% formic acid and acetonitrile (40/60, v/v) pumped at 0.2 mL/min. A high rate of acetonitrile was 
necessary to achieve a short analytical run due to lipophilic properties of colchicine (LogP=1.8 with a 
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pka=1.85). The total run time for the analysis was 2 min. Analysis was performed on a tandem mass 
spectrometer (TSQ Quantiva, Thermo, USA) equipped with an electrospray ionization source set in 
positive mode. An ion-spray voltage of +3.5 kV was applied. The heated capillary temperature was set 
at 300°C. Nitrogen was employed as sheath and auxiliary gas at a pressure of 35 and 10 arbitrary units, 
respectively. The argon gas collision-induced dissociation was used with a pressure of 1.5 mTorr. Data 
were collected in selected reaction monitoring (SRM) mode. In order to determine the MS transitions, 
two solutions (analyte and IS) were infused into the mass spectrometer using a syringe pump. The most 
intense product ions resulting from these fragmentations were m/z 400.2 → m/z 295.1 (used for 
quantification) and → m/z 310.1 for colchicine and m/z 403.25 → m/z 295.1 for colchicine D-3 at 
collision energy of 37 for all transitions. 
2.4. Sample preparation 
 
2.4.1. Total colchicine 
 
Drug-free human plasma samples were obtained from Etablissement Français du Sang, (Le Chesnay, 
France). Urine samples were collected from member of the laboratory personnel. To 200 µL of plasma 
or urine, 10 µL of internal standard were added. The determination of the total colchicine 
concentration required the denaturation of the Fab fragments after incubation in 5 volumes of water for 
plasma and 2 volumes for urine at 100°C, during 1 h according to the method described by Smith et al. 
for digoxin specific antibodies [27]. Mixture was then extracted by 3 mL n- 
hexane:dichloromethane:isopropanol (300:150:15, v:v:v) after adding 100 µL of phosphate buffer 2M 
(pH=8.4, adjusted by addition of sodium hydroxide). Samples were mixed for 10 min and then 
centrifuged at 3500 rpm for 10 min. The upper organic layer was decanted into another tube and 
evaporated to dryness under a nitrogen stream. Samples were reconstituted with 100 µL of mobile 
phase, vortex mixed for 10 s, and transferred into injection vials for analysis. In order to check the 
effectiveness of the method for degrading the Fab and releasing the colchicine, six plasma samples 
with 15 ng/mL of colchicine were spiked with an excess of Fab before heating. 
2.4.2. Free colchicine 
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A 200 µL volume of plasma or urine was placed in a Microcon centrifugal filter 30 KDa and 
centrifuged for 20 min at 13000 rpm, 100 µL of the ultra filtrate were transferred into another tube and 
10 µL of internal standard were added. Extraction was as described in section 2.4.1. In order to check 
the effectiveness of the method for separating Fab-bound and free colchicine, six plasma samples with 
15 ng/mL of colchicine were spiked with an excess of Fab before filtration. 
2.4.3. Organs 
 
Drug-free human liver samples were provided from former forensic cases. Fifty to 150 mg of liver 
were weighted and diluted with 3 parts of desionized water (v/w). The mixture was then ground 1 hour 
using a Tissue Lyser LT (Qiagen, Hilden, Germany) 50 oscillations per second after adding a steel 
ball. Then 100 µL of phosphate buffer 2M (pH=8.4), 10 µL of IS and 1 mL of dichloromethane were 
added to 20 µL of homogenates (corresponding to 5 mg of tissue) and mixed 15 min at 50 oscillations 
by second. After 10 min of centrifugation at 13000 rpm, the upper organic layer was decanted into 
another tube and evaporated to dryness under a nitrogen stream. Samples were reconstituted with 100 
µL of mobile phase, vortex mixed for 10 s, and transferred into injection vials for analysis. 
 
2.5. Method validation procedure 
 
2.5.1. Linearity 
 
Calibration curves included a blank sample, a zero sample, and seven CS over the concentration [0.5- 
100 ng/mL] range for plasma and urine, and [5-300 pg/mg] for liver. Calibration curves over a period 
of one month were taken into account for the determination of the best fit. The best fit among linear 
and quadratic equations was determined using various weighting factors of the inverse concentration 
(e.g. 1/x and 1/x²). The equation showing the lowest and most constant percentage total bias from 
nominal CS values was considered as the best-fit model. The IS method was used for quantification: 
analytes/IS ratios were plotted against the spiked concentrations. Back-calculated concentrations of the 
CS had to be within 85-115% of the nominal concentrations. 
2.5.2. Specificity, carry over 
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To investigate whether endogenous matrix constituents interfered with the assay, drug free matrix 
blank samples, zero samples and samples spiked at the LLOQ were analyzed according to the 
described procedure. Interferences with others drugs were investigated by analyzing a drug free matrix 
spiked with 1 µg/mL of analgesic and nonsteroidal anti-inflammatory drugs that could be used in acute 
gout treatment (acetaminophen, codeine, morphine, tramadol, salicylic acid, mefenamic acid, niflumic 
acid, nimesulide, ibuprofen, piroxicam, nabumetone, tiaprofenic acid, indomethacin, diclofenac, 
flurbiprofen, meloxicam, naproxen, sulindac, ketoprofen, rofecoxib, celecoxib). Assay specificity was 
defined by evidence of non-interference at retention times and ion channels identical to that of 
colchicine and IS in the blank samples. A blank sample was also analyzed immediately following the 
highest CS in each run to monitor the carry-over of analyte and IS. 
2.5.3. Lower limit of quantification and detection 
 
The LLOQ was defined as the lowest concentration for which an accuracy between 80% and 120% 
and a precision with a coefficient of variation of ± 20% or less that was obtained over six 
measurements. A QC was prepared in plasma, urine and in liver at the LLOQ and analyzed as the 
others QC levels. The limit of detection (LOD) was determined by analyzing serial dilutions in mobile 
phase of the LLOQ until obtaining the last concentration value with a signal to noise ratio >3. 
2.5.4. Accuracy and precision 
 
Accuracy (measured value/nominal value) and precision (coefficient of variation) were determined for 
three QC levels (low, medium and high level) in each matrix. Each QC level was processed six times 
three different days over a period of one month. The values obtained were analyzed using analysis of 
variance (ANOVA), which separated the intra-day and inter-day standard deviation and consequently 
the corresponding coefficients of variation (CV). An accuracy within the range 85-115% of the 
nominal values and a precision with a CV of ±15% were required, except for the LLOQ. 
2.5.5. Recovery and matrix effect 
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Three procedures (A, B and C) were performed on six different matrix sources for plasma, urine and 
liver at two concentrations (1.5-75 ng/mL for liquid matrices and 15-260 pg/mg for liver) in order to 
evaluate extraction yield and matrix effect (ME). (A) Analytes and the IS were spiked in the mobile 
phase and directly injected; (B) Analytes and the IS were spiked afterwards in extracted blank matrix 
samples and injected; and (C) Analytes and IS were spiked in plasma samples, the complete extraction 
procedure was carried through, and the samples were injected into the system. The mean 
chromatographic peaks obtained using the three procedures were compared. The ratios C/B, B/A 
determined the yield of extraction and the matrix effect, respectively. 
2.5.6. Stability 
 
Colchicine stability was investigated in plasma at four levels (QC levels and LOQ) after 24 hours at 
20±5°C, and after 24 hours and 72 hours at 5±3°C (n=6). Long term stability was evaluated through 1 
and 3 months at the same temperatures. Stability after three freeze/thaw cycles was also tested at the 
three QC levels (n=3). The stability of the vial inside the autosampler (8°C) was evaluated over 24 
hours by reinjection of QC and LOQ samples. Samples were considered stable if colchicine variation 
was less than 15% from initial value. 
2.6. Application 
 
One Göttingen mini-pig, age one year, and obtained from the Ellegaard Göttingen Minipigs A/S 
(Dalmose, Denmark) was used for this pre-clinical study. The study was approved by the Edinburgh 
University’s Ethical Review Committee and was licensed under the Animals (Scientific Procedures) 
Act 1986. The animal was weighed immediately before entering in the study (30 Kg). The animal was 
anesthetized before surgery, and remained anesthetized throughout the study under the care of the 
veterinary anesthetists. Central lines were inserted by “cut down” into the carotid artery and external 
jugular vein. Bladder catheterization was realized by mini laparotomy. Intra-venous fluids replacement 
with Hartmann’s solution began at induction of anesthesia (10 mL/Kg over 30 min then 5 mL/Kg/hr). 
The flow rate was increased as required to support central venous pressure. Approximately 30 min 
before dosing, colchicine was dissolved in physiological saline to achieve selected dose (0.25 mg/Kg). 
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Solution was administered intravenously over one hour. Three hours after the end of colchicine 
administration, the animal was treated with an equimolar dose of Fab administered over 1 h. Arterial 
blood samples were taken at -10 min pre-treatment and 1 h, 5 h and 48 h post-dosing. Plasma was 
separated by centrifugation at 4.000 rpm for 10 min and transferred to a -80°C freezer for subsequent 
storage within 48 hours of sampling. Urine was collected pre-treatment and 3 h, 6 h and 48 h post- 
treatment and immediately frozen, urine volume being recorded. The animal was euthanized by IV 
overdose with pentobarbital at the end of the experiment (48 h). For post-mortem examination, heart, 
liver, one kidney and a sample of muscle and small intestine were removed from the animal and rinsed 
with saline. A sample was frozen at -80°C and stored for subsequent colchicine analysis. 
 
 
3. Results 
 
3.1. Validation 
 
A chromatogram of a blank sample and plasma sample spiked with 0.5 ng/mL of colchicine (LOQ) are 
presented in figure 1. The retention times of colchicine and its IS was 1.55 min. No interference from 
constituents of drug-free human plasma and from all the others tested drugs at the retention times and 
the ion channels of colchicine and colchicine D-3 were observed. Mean carry-over was lower than 0.1 
% for colchicine and colchicine D-3. 
 
The calibration curves exhibited good linearity in the concentration range 0.5-100 ng/mL for plasma 
and urine, and 5-300 pg/mg for liver with 1/x weighting factor. Mean slopes, intercepts and 
determination coefficients are reported in table 1. Coefficient of variation (CV) and bias for the back- 
calculated concentrations of the calibration standards were all <15% and within 85-115% of the 
nominal concentrations, respectively (Table 1). 
Matrix effect and extraction recovery for plasma and liver are presented in table 2. 
 
LOQ and LOD were 0.5 ng/mL and 0.3 ng/mL for plasma and urine respectively, and 5 pg/mg and 3 
pg/mg for liver, respectively. Intra-day, inter-day CV and bias for LOQ and QC samples were lower 
than 15%. Inter-day CV and bias are presented in table 3. 
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Plasma levels of colchicine were stable under the different tested conditions exhibiting a variation 
lower than 15%. 
No free colchicine was found in plasma samples spiked with 15 ng/mL of colchicine and an excess of 
Fab before filtration. Conversely, the 15 ng/mL of colchicine were recovered following heating 
procedure, with a CV and a bias < 15%. 
3.2. Application 
 
Total and free colchicine obtained in plasma and urine are presented in table 4. Post-mortem 
colchicine levels measured in organs are presented in table 5. 
 
 
 
4. Discussion 
 
4.1. Validation 
 
Colchicine assay using LC-MS/MS after Fab administration required a separation of free and Fab- 
bound colchicine, allowing an accurate estimation of colchicine redistribution from tissue to blood. To 
our knowledge, only one method devoted to measure free and total colchicine has been published [24]. 
Sabouraud et al. developed a radio immunoassay (RIA) with colchicine-specific antibodies; separation 
of both free and Fab-bound colchicine was realized using the method described for digoxin and 
digitoxin by Smith et al. [26,27]. Separation was carried out by equilibrium dialysis overnight for free 
colchicine. Total colchicine was estimated after Fab denaturation by dilution of plasma in 5 volumes 
and urine in 2 volumes of water heated to 100 °C for 1h. These authors estimated that 90-94% of 
bound-colchicine was transformed in free colchicine with their method. Today, due to environmental 
and safety issues, RIA assays in clinical laboratories are restricted, requiring the development of a 
novel method. Recently, a LC-MS/MS method was developed by Peake et al. for the determination of 
total colchicine in plasma and urine following Fab administration in rats [28]. However, the authors 
gave no information regarding the LOQ, and colchicine recovery following Fab lysis. We presented 
here a simple method, requiring a shorter preparation step for free colchicine thanks to microfiltration. 
The weight of Fab fragments is close to 50 KDa, Fab-bound colchicine was separated with 30 KDa 
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filter after centrifugation, allowing free colchicine (399 Da) to pass. Due to the loss of sample during 
this step, a larger volume than required (200 µL) was filtered, and the analysis was done using 100 µL 
of filtrate. Internal standard was necessarily added after filtration to avoid deuterated colchicine 
fixation to Fab. 
Fab lysis was carried out using the method of Smith et al. with a good recovery since colchicine is not 
thermolabile [27]. When the analysis was done without heating, in the presence of Fab, we observed a 
total disappearance of deuterated colchicine and a loss of non-deuterated colchicine due to Fab 
fixation. Consequently, Fab lysis and colchicine release was assessed by deuterated colchicine 
recovery and by recovering the total colchicine of a spiked plasma with 15 ng/mL and an excess of 
Fab, showing that our lysis was complete and better than that obtained in the Sabouraud study (24). 
Despite a low sample volume (200µL) and a high sensitivity required (therapeutic plasma 
concentrations: 0.3-2.4 ng/mL), the LOQ of our method was 0.5 ng/mL with a LOD at 0.3 ng/mL [29]. 
For plasma dilution in 5 volumes of water compared to filtration, extraction recovery fell from 73-85% 
to 31-33% respectively. This observation is partially explained by an identical volume of solvent used 
for LLE despite a larger sample volume. In the same way, urine dilution in 2 volumes of water 
compared to filtration induces a decrease in extraction recovery from 78-90% to 65-69% respectively. 
However, this methodology was conserved for the validation since the LOQ was still acceptable 
despite this poor recovery. Three compositions of organic solvent were tested for LLE. Hexane (H), 
dichoromethane (D) and hexane:dichoromethane:isopropanol (300:150:15, v:v:v) (HDI) [30]. H 
presented a low colchicine recovery. D and HDI presented equivalent recoveries, but a higher matrix 
effect was observed in plasma with D. HDI was chosen for plasma and urine LLE. 
Few methods are described in literature for colchicine tissue analysis. A first procedure was developed 
for post-mortem organs by Rochdi et al. using RIA [22]. Later, Kintz et al. presented a novel method 
developed with HPLC/UV with a sensitivity similar to our (LOQ = 5 pg/mg) [15]. However, this 
procedure required a large sample (0.75g), a high volume of organic solvent (10 mL dichloromethane) 
and a longer analytical run (7.6 min). Recently, Peake et al. designed a study to evaluate colchicine 
specific Fab efficacy in a murine model of colchicine intoxication, with a LC-MS/MS procedure for 
colchicine measurements in plasma, urine and organs [28]. In this paper, samples homogenates were 
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diluted in methanol (1 part of sample plus 3 parts methanol) and directly injected in the system, but 
few information are given regarding the validation criteria of the method (limit of quantification, 
matrix effect, colchicine recovery). The procedure presented here required a low volume of sample 
(20µL of organ homogenates corresponding to 5mg of tissue), a low volume of organic solvent (1 mL 
of dichloromethane) and a short analytical run (2 min) with a good sensitivity. For the LLE in liver, 
contrary to plasma, a lower matrix effect was observed with D rather than HDI with equivalent 
recoveries, so D was chosen for liver extraction. LLE was initially performed by simple turning of the 
tube of homogenates leading to a low extraction yield. A dynamic extraction using the same procedure 
as liver homogenates production was then tested (50 oscillations by second after adding a steel ball) 
allowing achievement of an acceptable recovery (58-73%). 
4.2. Application 
 
The method was successfully applied to an animal intoxicated with colchicine and treated with a 
colchicine specific Fab. Concentrations observed for total colchicine were over our LOQ throughout 
the experiment after colchicine administration. Before Fab administration but after colchicine 
administration (T1h), free and total colchicine levels were similar both in plasma and urine, all the 
circulating colchicine being free. After Fab administration (T5h), colchicine was completely bound to 
Fab, free colchicine being under our LOQ both in plasma and in urine, showing the efficacy of the Fab 
to bind colchicine and that colchicine is also in the Fab-bound form in urine. After 48h, colchicine is 
present in both forms (free and Fab-bound) in particular in urine probably because of the Fab 
metabolism which alter Fab affinity for colchicine, as previously shown for digoxin-specific Fab [31]. 
Post-mortem organ analyses found similar concentrations between organs, ranging from 73 to 114 
pg/mg. Interpretation remains difficult since there is no data for colchicine levels in organs among 
pigs. Nevertheless, these data appeared low but probably because elimination of colchicine was 
already significant at 48h as shown by low concentrations in plasma and urine at that time. 
5. Conclusion 
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Two LC-MS/MS methods have been developed for the determination of free and Fab-bound 
colchicine in pig plasma and urine, and validated in both matrices. The methods require only 200 µl of 
sample, and allow a high throughput due to a short analytical run (2 min). A third method was 
developed for tissue analysis and validated in liver. All methods were successfully applied in real 
samples. This method will allow the pharmacokinetics /pharmacodynamics relationship studies on the 
efficacy of the Fab fragments in colchicine poisoning. 
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Fig 1. Colchicine ion chromatogram of a plasma blank sample (A); plasma sample spiked with 
colchicine at a concentration of 0.5 ng/mL (B); a real plasma sample (T5h after Fab infusion) with free 
colchicine < 0.5 ng/mL (C) and total colchicine at 110 ng/mL (D). 
Table 1. Mean slope, intercept, determination coefficient and calibration standard (CS) range 
(minimum and maximum), CV and bias for the different methods. 
Table 2. Mean matrix effect ± coefficient of variation (%) and extraction recovery in plasma and liver. 
Table 3. Intra-day and inter-day coefficient of variation and mean bias observed for the limit of 
quantification (n=6) and quality controls (n=6). 
Table 4. Total and free colchicine levels (ng/mL) in plasma and urine measured during the experiment. 
Table 5. Post-mortem colchicine levels found in organs. 
 Highlights : 
 
 
- Determination of free and Fab-bound colchicine following Fab fragments 
administration. 
 
 
- Three LC-MS/MS methods were designed and validated in plasma, urine and organs. 
 
 
- The methods require only 200 µl of sample, and allow a high throughput due to a 2 
min analytical run. 
 
 
- These methods were applied to a pig treated with colchicine specific Fab fragments. 
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Abstract 
 
Clinical evaluation of a colchicine specific antigen-binding fragment (Fab) in order to treat colchicine 
poisoning required the development of an accurate method allowing quantification of free and Fab- 
bound colchicine in plasma and urine, and free colchicine in tissues, to measure colchicine 
redistribution after Fab administration. Three methods have been developed for this purpose, and 
validated in plasma, urine and liver: total colchicine was determined after denaturation of Fab by 
dilution in water and heating; free colchicine was separated from Fab-bound colchicine by filtration 
with 30 KDa micro-filters; tissues were homogenized in a tissue mixer. Deuterated colchicine was 
used as internal standard. Samples were extracted by liquid-liquid extraction and analyzed with a LC- 
MS/MS. LOQ were 0.5 ng/mL in plasma and urine for free and total colchicine and 5 pg/mg in tissues. 
The methods were linear in the 0.5-100 ng/mL range in plasma and urine, and 5-300 pg/mg in tissues 
with determination coefficients > 0.99. Precision and accuracy of QC samples presented a CV < 9.4%. 
The methods require only 200 µl of sample and allow a high throughput due to short analytical run (2 
min). These methods were successfully applied to a pig intoxicated with colchicine and treated with 
colchicine specific Fab fragments. 
Keywords: colchicine; toxicology; mass spectrometry; immunoglobulin Fab fragments; antidote 
 
 
 
 
1. Introduction 
 
Colchicine is a tricyclic alkaloid extracted from Colchicum autumnale, used since historic times for 
acute gout [1]. Nowadays, colchicine is indicated in gouty arthritis, Behçet disease [2] and 
Mediterranean fever [3]. Colchicine is a potent inhibitor of tubulin polymerization and microtubules 
genesis, blocking cell mitosis and neutrophil phagocytosis. 
Colchicine presents a variable oral bioavailability ranging from 18 to 79% (mean 45%) among healthy 
volunteers and elderly people [4]. After oral administration of 1 mg of colchicine, plasma peak 
concentration is observed between 0.5 and 1.5 hours [5]. Colchicine is well distributed in tissues, with 
a distribution half-life and volume respectively ranging from 0.9 to 1.4 hours and 2.3 to 8.5 L/Kg [4]. 
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Among healthy subjects, the terminal half-life varies from 23 to 41 hours [4]. Less than 40% of a 
labeled oral dose of colchicine is excreted in urine [6]. 
Colchicine therapeutic dose is 0.015 mg/Kg, it can be toxic from 0.1 mg/Kg and lethal at 0.8 mg/Kg, 
exhibiting a narrow therapeutic index [7]. Intoxications are rare, but they are associated with high 
mortality [8–16]. The course of colchicine toxicity can be divided in three phases [17,18]. The first 
occurs within the first 24h after ingestion, with gastrointestinal symptomatology (mainly diarrhea). 
The second develops from 24 h to 72 h, and is manifested by multiorgan failure: disseminated 
intravascular coagulation (DIC), renal, liver, respiratory, bone marrow and cardiac failure. The third 
stage is characterized by organ recovery associated with a leukocytosis and alopecia. Currently, there 
is no treatment available for colchicine intoxication. Colchicine has been reported to be non-dialyzable 
due to a high distribution volume, and a low body clearance [19]. Colchicine presents a high 
dissociation constant (10-6 to 10-7 M at 37°C) with tubulin, with a dissociation half-life of the complex 
tubulin-colchicine ranging from 20 to 30 hours [20]. This observation explains the long colchicine 
half-life (20-60 h) among intoxicated patients which is closely related to the complex dissociation 
[21,22]. Following these observations, an immunotoxicotherapy was developed using colchicine 
specific fragment antigen-binding (Fab). This therapy was successfully applied in a murine model 
intoxicated with colchicine lethal doses [23]. In rabbits, after a non-lethal dose of colchicine, Fab alter 
colchicine disposition with an important redistribution from tissues to blood [24]. In 1995, a clinical 
case of colchicine intoxication was successfully treated with Fab [8]. Thereafter, in 1996, spongiform 
encephalopathy and mad cow disease have spread in Europe, and colchicine specific Fab production 
from ovine origin was stopped in France. Recently, a new colchicine specific Fab has been developed, 
with a high affinity for colchicine (Ka = 1011 M-1) [25]. 
The evaluation of treatment efficacy required a specific analytical method allowing free and Fab- 
bound colchicine to be distinguished following colchicine specific Fab treatment. A previous method 
was developed by radioimmunoassay (RIA) with colchicine specific antiserum, but RIA is used less 
today due to environmental and economic issues [26]. We present here two rapid and sensitive mass 
spectrometric methods able to assess free and total (free + Fab-bound) colchicine in plasma and urine, 
and a third assay in organs. 
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2. Material and methods 
 
2.1. Chemicals and reagents 
 
The HPLC grade acetonitrile, MS grade water, isopropanol and hexane were provided by Merck 
(Darmstadt, Germany). Ammonium formate, formic acid and dichloromethane standards were 
supplied by Sigma Aldrich (Saint-Louis, USA). Colchicine was provided from LGC standards 
(Teddington, United Kingdom) and colchicine D-3 from Toronto Research Medical (Toronto, 
Canada). Potassium dihydrophosphate (KH2 PO4) was purchased from VWR (Radnor, USA). 
Colchicine-specific Fab fragments were provided by Micropharm (Newcastle Emlyn, UK). Microcon 
 
centrifugal filters 30 KDa were purchased from Millipore (Merck, Darmstadt, Germany). 
 
2.2. Standard and quality control solutions 
 
Stock solutions of colchicine and colchicine D-3 (1 mg/mL) were prepared in methanol and stored for 
one year at – 20°C. Standards solutions were wrapped in aluminium foil to prevent photodegradation 
of colchicine. Working solutions of colchicine for calibration standards (CS) were prepared at three 
concentrations (1, 0.1 and 0.01 µg/mL) by dilution in MS grade water of the stock solution. Working 
solution of colchicine for quality control (QC) was prepared from another 1 mg/mL stock solution. A 
working internal standard solution (0.1 µg/mL) was prepared by dilution of colchicine D-3 stock 
solution with MS grade water. 
2.3. LC-MS/MS 
 
Colchicine concentrations were measured using an UPLC system (Dionex Ultimate 3000, Thermo, 
USA) coupled with a tandem mass spectrometer (TSQ Quantiva, Thermo, USA). Analyte separation 
was carried out on a Hypersil GOLD Thermo column (100 x 2.1mm, 1.9 µm) maintained at 30°C. The 
device was completed with a pre-column (Thermo Hypersil GOLD 10 x 2.1mm, 5µm). Elution was in 
isocratic mode with a mobile phase composed by a mixture of 2 mM ammonium formate containing 
0.1% formic acid and acetonitrile (40/60, v/v) pumped at 0.2 mL/min. A high rate of acetonitrile was 
necessary to achieve a short analytical run due to lipophilic properties of colchicine (LogP=1.8 with a 
5  
pka=1.85). The total run time for the analysis was 2 min. Analysis was performed on a tandem mass 
spectrometer (TSQ Quantiva, Thermo, USA) equipped with an electrospray ionization source set in 
positive mode. An ion-spray voltage of +3.5 kV was applied. The heated capillary temperature was set 
at 300°C. Nitrogen was employed as sheath and auxiliary gas at a pressure of 35 and 10 arbitrary units, 
respectively. The argon gas collision-induced dissociation was used with a pressure of 1.5 mTorr. Data 
were collected in selected reaction monitoring (SRM) mode. In order to determine the MS transitions, 
two solutions (analyte and IS) were infused into the mass spectrometer using a syringe pump. The most 
intense product ions resulting from these fragmentations were m/z 400.2 → m/z 295.1 (used for 
quantification) and → m/z 310.1 for colchicine and m/z 403.25 → m/z 295.1 for colchicine D-3 at 
collision energy of 37 for all transitions. 
2.4. Sample preparation 
 
2.4.1. Total colchicine 
 
Drug-free human plasma samples were obtained from Etablissement Français du Sang, (Le Chesnay, 
France). Urine samples were collected from member of the laboratory personnel. To 200 µL of plasma 
or urine, 10 µL of internal standard were added. The determination of the total colchicine 
concentration required the denaturation of the Fab fragments after incubation in 5 volumes of water for 
plasma and 2 volumes for urine at 100°C, during 1 h according to the method described by Smith et al. 
for digoxin specific antibodies [27]. Mixture was then extracted by 3 mL n- 
hexane:dichloromethane:isopropanol (300:150:15, v:v:v) after adding 100 µL of phosphate buffer 2M 
(pH=8.4, adjusted by addition of sodium hydroxide). Samples were mixed for 10 min and then 
centrifuged at 3500 rpm for 10 min. The upper organic layer was decanted into another tube and 
evaporated to dryness under a nitrogen stream. Samples were reconstituted with 100 µL of mobile 
phase, vortex mixed for 10 s, and transferred into injection vials for analysis. In order to check the 
effectiveness of the method for degrading the Fab and releasing the colchicine, six plasma samples 
with 15 ng/mL of colchicine were spiked with an excess of Fab before heating. 
2.4.2. Free colchicine 
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A 200 µL volume of plasma or urine was placed in a Microcon centrifugal filter 30 KDa and 
centrifuged for 20 min at 13000 rpm, 100 µL of the ultra filtrate were transferred into another tube and 
10 µL of internal standard were added. Extraction was as described in section 2.4.1. In order to check 
the effectiveness of the method for separating Fab-bound and free colchicine, six plasma samples with 
15 ng/mL of colchicine were spiked with an excess of Fab before filtration. 
2.4.3. Organs 
 
Drug-free human liver samples were provided from former forensic cases. Fifty to 150 mg of liver 
were weighted and diluted with 3 parts of desionized water (v/w). The mixture was then ground 1 hour 
using a Tissue Lyser LT (Qiagen, Hilden, Germany) 50 oscillations per second after adding a steel 
ball. Then 100 µL of phosphate buffer 2M (pH=8.4), 10 µL of IS and 1 mL of dichloromethane were 
added to 20 µL of homogenates (corresponding to 5 mg of tissue) and mixed 15 min at 50 oscillations 
by second. After 10 min of centrifugation at 13000 rpm, the upper organic layer was decanted into 
another tube and evaporated to dryness under a nitrogen stream. Samples were reconstituted with 100 
µL of mobile phase, vortex mixed for 10 s, and transferred into injection vials for analysis. 
 
2.5. Method validation procedure 
 
2.5.1. Linearity 
 
Calibration curves included a blank sample, a zero sample, and seven CS over the concentration [0.5- 
100 ng/mL] range for plasma and urine, and [5-300 pg/mg] for liver. Calibration curves over a period 
of one month were taken into account for the determination of the best fit. The best fit among linear 
and quadratic equations was determined using various weighting factors of the inverse concentration 
(e.g. 1/x and 1/x²). The equation showing the lowest and most constant percentage total bias from 
nominal CS values was considered as the best-fit model. The IS method was used for quantification: 
analytes/IS ratios were plotted against the spiked concentrations. Back-calculated concentrations of the 
CS had to be within 85-115% of the nominal concentrations. 
2.5.2. Specificity, carry over 
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To investigate whether endogenous matrix constituents interfered with the assay, drug free matrix 
blank samples, zero samples and samples spiked at the LLOQ were analyzed according to the 
described procedure. Interferences with others drugs were investigated by analyzing a drug free matrix 
spiked with 1 µg/mL of analgesic and nonsteroidal anti-inflammatory drugs that could be used in acute 
gout treatment (acetaminophen, codeine, morphine, tramadol, salicylic acid, mefenamic acid, niflumic 
acid, nimesulide, ibuprofen, piroxicam, nabumetone, tiaprofenic acid, indomethacin, diclofenac, 
flurbiprofen, meloxicam, naproxen, sulindac, ketoprofen, rofecoxib, celecoxib). Assay specificity was 
defined by evidence of non-interference at retention times and ion channels identical to that of 
colchicine and IS in the blank samples. A blank sample was also analyzed immediately following the 
highest CS in each run to monitor the carry-over of analyte and IS. 
2.5.3. Lower limit of quantification and detection 
 
The LLOQ was defined as the lowest concentration for which an accuracy between 80% and 120% 
and a precision with a coefficient of variation of ± 20% or less that was obtained over six 
measurements. A QC was prepared in plasma, urine and in liver at the LLOQ and analyzed as the 
others QC levels. The limit of detection (LOD) was determined by analyzing serial dilutions in mobile 
phase of the LLOQ until obtaining the last concentration value with a signal to noise ratio >3. 
2.5.4. Accuracy and precision 
 
Accuracy (measured value/nominal value) and precision (coefficient of variation) were determined for 
three QC levels (low, medium and high level) in each matrix. Each QC level was processed six times 
three different days over a period of one month. The values obtained were analyzed using analysis of 
variance (ANOVA), which separated the intra-day and inter-day standard deviation and consequently 
the corresponding coefficients of variation (CV). An accuracy within the range 85-115% of the 
nominal values and a precision with a CV of ±15% were required, except for the LLOQ. 
2.5.5. Recovery and matrix effect 
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Three procedures (A, B and C) were performed on six different matrix sources for plasma, urine and 
liver at two concentrations (1.5-75 ng/mL for liquid matrices and 15-260 pg/mg for liver) in order to 
evaluate extraction yield and matrix effect (ME). (A) Analytes and the IS were spiked in the mobile 
phase and directly injected; (B) Analytes and the IS were spiked afterwards in extracted blank matrix 
samples and injected; and (C) Analytes and IS were spiked in plasma samples, the complete extraction 
procedure was carried through, and the samples were injected into the system. The mean 
chromatographic peaks obtained using the three procedures were compared. The ratios C/B, B/A 
determined the yield of extraction and the matrix effect, respectively. 
2.5.6. Stability 
 
Colchicine stability was investigated in plasma at four levels (QC levels and LOQ) after 24 hours at 
20±5°C, and after 24 hours and 72 hours at 5±3°C (n=6). Long term stability was evaluated through 1 
and 3 months at the same temperatures. Stability after three freeze/thaw cycles was also tested at the 
three QC levels (n=3). The stability of the vial inside the autosampler (8°C) was evaluated over 24 
hours by reinjection of QC and LOQ samples. Samples were considered stable if colchicine variation 
was less than 15% from initial value. 
2.6. Application 
 
One Göttingen mini-pig, age one year, and obtained from the Ellegaard Göttingen Minipigs A/S 
(Dalmose, Denmark) was used for this pre-clinical study. The study was approved by the Edinburgh 
University’s Ethical Review Committee and was licensed under the Animals (Scientific Procedures) 
Act 1986. The animal was weighed immediately before entering in the study (30 Kg). The animal was 
anesthetized before surgery, and remained anesthetized throughout the study under the care of the 
veterinary anesthetists. Central lines were inserted by “cut down” into the carotid artery and external 
jugular vein. Bladder catheterization was realized by mini laparotomy. Intra-venous fluids replacement 
with Hartmann’s solution began at induction of anesthesia (10 mL/Kg over 30 min then 5 mL/Kg/hr). 
The flow rate was increased as required to support central venous pressure. Approximately 30 min 
before dosing, colchicine was dissolved in physiological saline to achieve selected dose (0.25 mg/Kg). 
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Solution was administered intravenously over one hour. Three hours after the end of colchicine 
administration, the animal was treated with an equimolar dose of Fab administered over 1 h. Arterial 
blood samples were taken at -10 min pre-treatment and 1 h, 5 h and 48 h post-dosing. Plasma was 
separated by centrifugation at 4.000 rpm for 10 min and transferred to a -80°C freezer for subsequent 
storage within 48 hours of sampling. Urine was collected pre-treatment and 3 h, 6 h and 48 h post- 
treatment and immediately frozen, urine volume being recorded. The animal was euthanized by IV 
overdose with pentobarbital at the end of the experiment (48 h). For post-mortem examination, heart, 
liver, one kidney and a sample of muscle and small intestine were removed from the animal and rinsed 
with saline. A sample was frozen at -80°C and stored for subsequent colchicine analysis. 
 
 
3. Results 
 
3.1. Validation 
 
A chromatogram of a blank sample and plasma sample spiked with 0.5 ng/mL of colchicine (LOQ) are 
presented in figure 1. The retention times of colchicine and its IS was 1.55 min. No interference from 
constituents of drug-free human plasma and from all the others tested drugs at the retention times and 
the ion channels of colchicine and colchicine D-3 were observed. Mean carry-over was lower than 0.1 
% for colchicine and colchicine D-3. 
 
The calibration curves exhibited good linearity in the concentration range 0.5-100 ng/mL for plasma 
and urine, and 5-300 pg/mg for liver with 1/x weighting factor. Mean slopes, intercepts and 
determination coefficients are reported in table 1. Coefficient of variation (CV) and bias for the back- 
calculated concentrations of the calibration standards were all <15% and within 85-115% of the 
nominal concentrations, respectively (Table 1). 
Matrix effect and extraction recovery for plasma and liver are presented in table 2. 
 
LOQ and LOD were 0.5 ng/mL and 0.3 ng/mL for plasma and urine respectively, and 5 pg/mg and 3 
pg/mg for liver, respectively. Intra-day, inter-day CV and bias for LOQ and QC samples were lower 
than 15%. Inter-day CV and bias are presented in table 3. 
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Plasma levels of colchicine were stable under the different tested conditions exhibiting a variation 
lower than 15%. 
No free colchicine was found in plasma samples spiked with 15 ng/mL of colchicine and an excess of 
Fab before filtration. Conversely, the 15 ng/mL of colchicine were recovered following heating 
procedure, with a CV and a bias < 15%. 
3.2. Application 
 
Total and free colchicine obtained in plasma and urine are presented in table 4. Post-mortem 
colchicine levels measured in organs are presented in table 5. 
 
 
 
4. Discussion 
 
4.1. Validation 
 
Colchicine assay using LC-MS/MS after Fab administration required a separation of free and Fab- 
bound colchicine, allowing an accurate estimation of colchicine redistribution from tissue to blood. To 
our knowledge, only one method devoted to measure free and total colchicine has been published [24]. 
Sabouraud et al. developed a radio immunoassay (RIA) with colchicine-specific antibodies; separation 
of both free and Fab-bound colchicine was realized using the method described for digoxin and 
digitoxin by Smith et al. [26,27]. Separation was carried out by equilibrium dialysis overnight for free 
colchicine. Total colchicine was estimated after Fab denaturation by dilution of plasma in 5 volumes 
and urine in 2 volumes of water heated to 100 °C for 1h. These authors estimated that 90-94% of 
bound-colchicine was transformed in free colchicine with their method. Today, due to environmental 
and safety issues, RIA assays in clinical laboratories are restricted, requiring the development of a 
novel method. Recently, a LC-MS/MS method was developed by Peake et al. for the determination of 
total colchicine in plasma and urine following Fab administration in rats [28]. However, the authors 
gave no information regarding the LOQ, and colchicine recovery following Fab lysis. We presented 
here a simple method, requiring a shorter preparation step for free colchicine thanks to microfiltration. 
The weight of Fab fragments is close to 50 KDa, Fab-bound colchicine was separated with 30 KDa 
11  
filter after centrifugation, allowing free colchicine (399 Da) to pass. Due to the loss of sample during 
this step, a larger volume than required (200 µL) was filtered, and the analysis was done using 100 µL 
of filtrate. Internal standard was necessarily added after filtration to avoid deuterated colchicine 
fixation to Fab. 
Fab lysis was carried out using the method of Smith et al. with a good recovery since colchicine is not 
thermolabile [27]. When the analysis was done without heating, in the presence of Fab, we observed a 
total disappearance of deuterated colchicine and a loss of non-deuterated colchicine due to Fab 
fixation. Consequently, Fab lysis and colchicine release was assessed by deuterated colchicine 
recovery and by recovering the total colchicine of a spiked plasma with 15 ng/mL and an excess of 
Fab, showing that our lysis was complete and better than that obtained in the Sabouraud study (24). 
Despite a low sample volume (200µL) and a high sensitivity required (therapeutic plasma 
concentrations: 0.3-2.4 ng/mL), the LOQ of our method was 0.5 ng/mL with a LOD at 0.3 ng/mL [29]. 
For plasma dilution in 5 volumes of water compared to filtration, extraction recovery fell from 73-85% 
to 31-33% respectively. This observation is partially explained by an identical volume of solvent used 
for LLE despite a larger sample volume. In the same way, urine dilution in 2 volumes of water 
compared to filtration induces a decrease in extraction recovery from 78-90% to 65-69% respectively. 
However, this methodology was conserved for the validation since the LOQ was still acceptable 
despite this poor recovery. Three compositions of organic solvent were tested for LLE. Hexane (H), 
dichoromethane (D) and hexane:dichoromethane:isopropanol (300:150:15, v:v:v) (HDI) [30]. H 
presented a low colchicine recovery. D and HDI presented equivalent recoveries, but a higher matrix 
effect was observed in plasma with D. HDI was chosen for plasma and urine LLE. 
Few methods are described in literature for colchicine tissue analysis. A first procedure was developed 
for post-mortem organs by Rochdi et al. using RIA [22]. Later, Kintz et al. presented a novel method 
developed with HPLC/UV with a sensitivity similar to our (LOQ = 5 pg/mg) [15]. However, this 
procedure required a large sample (0.75g), a high volume of organic solvent (10 mL dichloromethane) 
and a longer analytical run (7.6 min). Recently, Peake et al. designed a study to evaluate colchicine 
specific Fab efficacy in a murine model of colchicine intoxication, with a LC-MS/MS procedure for 
colchicine measurements in plasma, urine and organs [28]. In this paper, samples homogenates were 
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diluted in methanol (1 part of sample plus 3 parts methanol) and directly injected in the system, but 
few information are given regarding the validation criteria of the method (limit of quantification, 
matrix effect, colchicine recovery). The procedure presented here required a low volume of sample 
(20µL of organ homogenates corresponding to 5mg of tissue), a low volume of organic solvent (1 mL 
of dichloromethane) and a short analytical run (2 min) with a good sensitivity. For the LLE in liver, 
contrary to plasma, a lower matrix effect was observed with D rather than HDI with equivalent 
recoveries, so D was chosen for liver extraction. LLE was initially performed by simple turning of the 
tube of homogenates leading to a low extraction yield. A dynamic extraction using the same procedure 
as liver homogenates production was then tested (50 oscillations by second after adding a steel ball) 
allowing achievement of an acceptable recovery (58-73%). 
4.2. Application 
 
The method was successfully applied to an animal intoxicated with colchicine and treated with a 
colchicine specific Fab. Concentrations observed for total colchicine were over our LOQ throughout 
the experiment after colchicine administration. Before Fab administration but after colchicine 
administration (T1h), free and total colchicine levels were similar both in plasma and urine, all the 
circulating colchicine being free. After Fab administration (T5h), colchicine was completely bound to 
Fab, free colchicine being under our LOQ both in plasma and in urine, showing the efficacy of the Fab 
to bind colchicine and that colchicine is also in the Fab-bound form in urine. After 48h, colchicine is 
present in both forms (free and Fab-bound) in particular in urine probably because of the Fab 
metabolism which alter Fab affinity for colchicine, as previously shown for digoxin-specific Fab [31]. 
Post-mortem organ analyses found similar concentrations between organs, ranging from 73 to 114 
pg/mg. Interpretation remains difficult since there is no data for colchicine levels in organs among 
pigs. Nevertheless, these data appeared low but probably because elimination of colchicine was 
already significant at 48h as shown by low concentrations in plasma and urine at that time. 
5. Conclusion 
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Two LC-MS/MS methods have been developed for the determination of free and Fab-bound 
colchicine in pig plasma and urine, and validated in both matrices. The methods require only 200 µl of 
sample, and allow a high throughput due to a short analytical run (2 min). A third method was 
developed for tissue analysis and validated in liver. All methods were successfully applied in real 
samples. This method will allow the pharmacokinetics /pharmacodynamics relationship studies on the 
efficacy of the Fab fragments in colchicine poisoning. 
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Legend 
 
 
Fig 1. Colchicine ion chromatogram of a plasma blank sample (A); plasma sample spiked with 
colchicine at a concentration of 0.5 ng/mL (B); a real plasma sample (T5h after Fab infusion) with free 
colchicine < 0.5 ng/mL (C) and total colchicine at 110 ng/mL (D). 
Table 1. Mean slope, intercept, determination coefficient and calibration standard (CS) range 
(minimum and maximum), CV and bias for the different methods. 
Table 2. Mean matrix effect ± coefficient of variation (%) and extraction recovery in plasma and liver. 
Table 3. Intra-day and inter-day coefficient of variation and mean bias observed for the limit of 
quantification (n=6) and quality controls (n=6). 
Table 4. Total and free colchicine levels (ng/mL) in plasma and urine measured during the experiment. 
Table 5. Post-mortem colchicine levels found in organs. 
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